This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Westlake Village-based Dole is publicly traded once again, after raising $400 million in a July 30 initial public offering. The IPO was a bit of a letdown for Dole. The company priced its shares at $16 only to see them open at $15 and then drop to $14.50 by the end of the trading day, Read More →
LTC Properties saw its net income soar a year after the pandemic caused serious interruptions to the real estate investment trust’s business model. On July 29, the Westlake Village-based REIT reported its net income for the second quarter of 2021 at $18.1 million, or 46 cents per share — an increase of more than 900% Read More →
InVia Robotics, a Westlake Village-based warehouse automation solution company, secured $30 million in a Series C funding round announced July 28, led by M12, Microsoft’s venture fund, and Qualcomm Ventures. To date, inVia has raised $59 million in funding. With this investment, inVia said it plans to extend its products’ reach and operational support in Read More →
Teledyne Technologies crushed analysts’ expectations July 28, delivering revenue in the second quarter of 2021 that doubled its total from the same quarter a year ago, thanks in large part to its acquisition of Flir systems, an Oregon based company with significant operations in Goleta. Teledyne, a Thousand Oaks-based industrial and scientific conglomerate, generated $1.12 Read More →
Amgen announced July 27 that it plans to buy a privately held Bay Area biotech company called TeneoBio in an all-cash deal worth as much as $2.5 billion. The deal is expected to close in the second half of this year and calls for Amgen to pay $900 million up front for all outstanding shares Read More →